Search

Your search keyword '"Imai, Kentaro"' showing total 387 results
Start Over Author "Imai, Kentaro"
387 results on '"Imai, Kentaro"'

6. ADJUVANT PEMBROLIZUMAB FOR RENAL CELL CARCINOMA (KEYNOTE-564): EXPLORATORY ANALYSIS ACROSS UCLA INTEGRATED STAGING SYSTEM RISK GROUPS AND DISEASE STAGE

Author

Zhang, Tian, primary, Choueiri, Toni K., additional, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Tom, additional, Symeonides, Stefan N., additional, Hajek, Jaroslav, additional, Chang, Yen-Hwa, additional, Lee, Jae-Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B., additional, Sawrycki, Piotr, additional, Xu, Lei, additional, Imai, Kentaro, additional, Poehlein, Christian, additional, and Powles, Thomas, additional

Published
2024
Full Text
View/download PDF

8. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Tomczak, Piotr, Choueiri, Toni, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas R., Hajek, Jaroslav, Lin, Tzu-Ping, Symeonides, Stefan N., Lee, Jae Lyun, Sawrycki, Piotr, Haas, Naomi B., Gurney, Howard P., Mahave, Mauricio, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Chevreau, Christine, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Topart, Delphine, Oudard, Stephane, Kopyltsov, Evgeniy, Hammers, Hans-Joerg, Quinn, David I., Alva, Ajjai, Menezes, Juliana de Janoski, Silva, Adriano Goncalves e, Winquist, Eric W., Hamzaj, Alketa, Procopio, Giuseppe, Karaszewska, Boguslawa, Nowakowska-Zajdel, Ewa M., Alekseev, Boris Y., Gafanov, Rustem A., Izmailov, Adel, Semenov, Andrey, Afanasyev, Sergey G., Lipatov, Oleg N., Powles, Thomas B., Srinivas, Sandy, McDermott, David, Kochuparambil, Samith T., Davis, Ian D., Peltola, Katriina, Sabbatini, Roberto, Chung, Jinsoo, Shkolnik, Michail I., Matveev, Vsevolod B., Gajate Borau, Pablo, McCune, Steven, Hutson, Thomas E., Dri, Alejandro, Sales, Silvio Correia, Yeung, Carrie, Alcala Castro, Carmen Marcela, Bostrom, Peter, Laguerre, Brigitte, Buttigliero, Consuelo, de Giorgi, Ugo, Fomin, Eugeniy A., Zakharia, Yousef, Hwang, Clara, Singer, Eric A., Yorio, Jeffrey T., Waterhouse, David, Kowalyszyn, Ruben Dario, Alfie, Margarita Sonia, Yanez Ruiz, Eduardo, Buchler, Tomas, Kankaanranta, Krista, Ferretti, Gianluigi, Kimura, Go, Nishimura, Kazuo, Masumori, Naoya, Tamada, Satoshi, Kato, Haruaki, Kitamura, Hiroshi, Danielewicz, Iwona, Wojcik-Tomaszewska, Joanna, Sala Gonzalez, Nuria, Chiu, Kun-Yuan, Atkins, Michael B., Heath, Elisabeth, Rojas-Uribe, Gustavo Adolfo, Gonzalez Fernandez, Manuel Enrique, Feyerabend, Susan, Pignata, Sandro, Numakura, Kazuyuki, Cybulska Stopa, Bozena, Zukov, Ruslan, Climent Duran, Miguel Angel, Maroto Rey, Pablo Jose, Montesa Pino, Alvaro, Chang, Chao-Hsiang, Vengalil, Salil, Waddell, Tom S., Cobb, Patrick W., Hauke, Ralph, Anderson, Daniel M., Sarantopoulos, John, Gourdin, Theodore, Zhang, Tian, Jayram, Gautam, Fein, Luis Enrique, Harris, Carole, Beato, Patricia Medeiros Milhomem, Flores, Francisco, Estay, Angela, Rubiano, Juan Andres, Bedke, Jens, Hauser, Stefan, Neisius, Andreas, Busch, Jonas, Anai, Satoshi, Tsunemori, Hiroyuki, Sawka, Dariusz, Sikora-Kupis, Bozena, Arranz, Jose Angel, Delgado, Ignacio, Chen, Chung-Hsin, Gunderson, Elizabeth, Tykodi, Scott, Koletsky, Alan, Chen, Kevin, Agrawal, Manish, Kaen, Diego Lucas, Sade, Juan Pablo, Tatangelo, Marcelo Daniel, Parnis, Francis, Barbosa, Fernando Maciel, Faucher, Genevieve, Iqbal, Nayyer, Marceau, Daniele, Paradis, Jean-Benoit, Hanna, Nawar, Acevedo, Alejandro, Ibanez, Carolina, Villanueva, Luis, Galaz, Pedro Pablo, Durango, Isabel Cristina, Manneh, Ray, Kral, Zdenek, Holeckova, Petra, Hakkarainen, Heikki, Ronkainen, Hanna, Abadie-Lacourtoisie, Sophie, Tartas, Sophie, Goebell, Peter J., Grimm, Marc-Oliver, Hoefner, Thomas, Wirth, Manfred, Panic, Andrej, Schultze-Seemann, Wolfgang, Yokomizo, Akira, Mizuno, Ryuichi, Uemura, Hirotsugu, Eto, Masatoshi, Tsujihata, Masao, Matsukawa, Yoshihisa, Murakami, Yoji, Kim, Miso, Hamberg, Paul, Marczewska-Skrodzka, Malgorzata, Szczylik, Cezary, Humphreys, Alison C., Jiang, Peter, Kumar, Birendra, Lu, Gary, Desai, Arpita, Karam, Jose Antonio, Keogh, George, Fleming, Mark, Zarba, Juan Jose, Leiva, Viviana E., Mendez, Guillermo Ariel, Harris, Samuel J., Brown, Stephen J., Antonio Junior, Joao Neif, Costamilan, Rita de Cassia, Rocha, Roberto Odebrecht, Muniz, David, Brust, Leandro, Lalani, Aly-Khan, Graham, Jeffrey, Levesque, Michael, Orlandi, Francisco, Kotasek, Rostislav, Deville, Jean L., Borchiellini, Delphine, Merseburger, Axel, Rink, Michael, Roos, Frederik, McDermott, Ray, Oyama, Masafumi, Yamamoto, Yoshiaki, Tomita, Yoshihiko, Miura, Yuji, Ioritani, Naomasa, Westgeest, Hans, Kubiatowski, Tomasz, Bal, Wieslaw, Girones Sarrio, Regina, Rowe, Julie, Prow, Debra M., Senecal, Francis, Hashemi-Sadraei, Neda, Cole, Scott W., Kendall, Stephan D., Richards, Donald A., Schnadig, Ian D., Gupta, Mukul, Powles, Thomas, Ferguson, Thomas, Symeonides, Stefan N, Gurney, Howard, Chang, Yen-Hwa, Haas, Naomi B, Burgents, Joseph E, Xu, Lei, Imai, Kentaro, Quinn, David I, and Choueiri, Toni K

Published
2022
Full Text
View/download PDF

10. Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups.

Author

Karam, Jose A., Bhattacharya, Rituparna, Ogbomo, Adesuwa, Gautam, Santosh, Yu, Rebekah, Sundaram, Murali, Imai, Kentaro, Chhabra, Jatin, and Haas, Naomi B.

Subjects
RENAL cell carcinoma, NEPHRECTOMY, OVERALL survival, PROGRESSION-free survival, SURVIVAL rate
Abstract

Objectives: To examine real‐world characteristics, journey, and outcomes among patients with locoregional, nonmetastatic renal cell carcinoma (RCC). Methods: A retrospective analysis of medical records from the ConcertAI Oncology Dataset was performed on adults in the United States with newly diagnosed nonmetastatic RCC between January 2012–December 2017 who received surgical treatment, and were followed until August 2021. Patients were stratified based on the risk of recurrence after nephrectomy. Recurrence rate and survival outcomes were assessed. Results: The cohort (n = 439) had a median age of 64 years, 66.1% were male, and 76.5% had clear‐cell histology. The median follow‐up time from nephrectomy was 39.3 months overall, 41.0 months for intermediate‐high‐risk patients (n = 377; 85.9%) and 24.1 months for high‐risk patients (n = 62; 14.1%). For intermediate‐high‐ and high‐risk patients, respectively, 68.4% and 56.5% had ≥1 medical oncologist visit after nephrectomy. Of 260 patients with documentation of postoperative imaging assessments, 72% were ordered by medical oncologists, and the median time from initial nephrectomy to the first scan was 110 days (intermediate‐high‐risk) and 51 days (high‐risk). Provider‐documented recurrence occurred in 223 (50.8%) patients, of whom 41.7% had ≥1 medical oncologist visit before the recurrence. Three‐year disease‐free survival (DFS), and overall survival rates were 49.4% and 80.8% (all patients): 27.7% and 64.7% (high‐risk); and 52.9% and 83.3% (intermediate‐high‐risk). Conclusions: Our study reports low DFS after nephrectomy for patients with intermediate‐high‐ and high‐risk RCC. Subsequent approval and use of new and newly approved adjuvant therapeutic options could potentially delay or prevent recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca

Published
2021
Full Text
View/download PDF

18. Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.

Author

Fong, Peter C.C., Kwiatkowski, Mariusz, Mosca, Alessandra, Perez Valderrama, Begona, Huang, Yi-Hsiu, Zedan, Ahmed H., Kuc, Kamil, Wiechno, Pawel, Laguerre, Brigitte, Gonzalez-Billalabeitia, Enrique, Osipov, Mikhail, Sener Dede, Didem, Goh, Jeffrey, Daugaard, Gedske, Zhu, Pengfei, Imai, Kentaro, liu, yingjie, and Arranz Arija, Jose Angel

Published
2024
Full Text
View/download PDF

19. Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.

Author

Augustin, Marinela, Laguerre, Brigitte, Baldini, Capucine, Zedan, Ahmed H., Gonzalez-Billalabeitia, Enrique, Fong, Peter C.C., Zukov, Ruslan, Hammerer, Peter, Prentice, Mark, Shore, Neal D., Necchi, Andrea, Todenhöfer, Tilman, Kessler, Elizabeth R., Köse, Fatih, Gurney, Howard, Perez Valderrama, Begona, Zhu, Pengfei, Imai, Kentaro, liu, yingjie, and McDermott, Raymond S.

Published
2024
Full Text
View/download PDF

34. Long non-coding RNA lnc-CHAF1B-3 promotes renal interstitial fibrosis by regulating EMT-related genes in renal proximal tubular cells

Author

Imai, Kentaro, primary, Ishimoto, Takuji, additional, Doke, Tomohito, additional, Tsuboi, Toshiki, additional, Watanabe, Yu, additional, Katsushima, Keisuke, additional, Suzuki, Miho, additional, Oishi, Hideto, additional, Furuhashi, Kazuhiro, additional, Ito, Yasuhiko, additional, Kondo, Yutaka, additional, and Maruyama, Shoichi, additional

Published
2023
Full Text
View/download PDF

36. Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

Author

Choueiri, Toni K., primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Tom, additional, Symeonides, Stefan N., additional, Hajek, Jaroslav, additional, Chang, Yen-Hwa, additional, Lee, Jae-Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B., additional, Sawrycki, Piotr, additional, Zhang, Tian, additional, Xu, Lei, additional, Imai, Kentaro, additional, Poehlein, Christian Heinrich, additional, and Powles, Thomas, additional

Published
2023
Full Text
View/download PDF

40. Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non–Muscle-Invasive Bladder Cancer.

Author

Narayan, Vikram M., Siolas, Despina, Meadows, Eric S., Turzhitsky, Vladimir, Sillah, Arthur, Imai, Kentaro, McMurry, Andrew J., and Li, Haojie

Subjects
NON-muscle invasive bladder cancer, NATURAL language processing, MEDICAL terminology, CANCER diagnosis, ELECTRONIC health records, DEEP learning
Abstract

PURPOSE: Treatment of non–muscle-invasive bladder cancer (NMIBC) is guided by risk stratification using clinical and pathologic criteria. This study aimed to develop a natural language processing (NLP) model for identifying patients with high-risk NMIBC retrospectively from unstructured electronic medical records (EMRs) and to apply the model to describe patient and tumor characteristics. METHODS: We used three independent EMR-derived data sets including adult patients with a bladder cancer diagnosis in 2011-2020 for NLP model development and training (n = 140), validation (n = 697), and application for the retrospective cohort analysis (n = 4,402). Deep learning methods were used to train NLP recognition of medical chart terminology to identify seven high-risk NMIBC criteria; model performance was assessed using the F1 score, weighted across features. An algorithm was then used to classify each patient as high-risk NMIBC (yes/no). Manually reviewed records served as the gold standard. RESULTS: The F1 scores after model training were >0.7 for all but one uncommon feature (prostatic urethral involvement). The highest area under the receiver operating curves (AUC) was observed for Ta (0.897) and T1 (0.897); the lowest AUC was for carcinoma in situ (CIS; 0.617). For high-risk NMIBC classification, positive predictive value was 79.4%, negative predictive value was 93.2%, and false-positive rate was 8.9%. Sensitivity and specificity were 83.7% and 91.1%, respectively. Of 748 patients manually confirmed as having high-risk NMIBC, 196 (26%) had CIS (of whom 19% also had T1 and 23% also had Ta disease); 552 tumors (74%) had no associated CIS. CONCLUSION: The NLP model, combined with a rule-based algorithm, identified high-risk NMIBC with good performance and will enable future work to study real-world treatment patterns and clinical outcomes for high-risk NMIBC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.

Author

Yizhen Lai, Bensimon, Arielle G., Gao, Emily, Bhattacharya, Rituparna, Ruifeng Xu, Chevure, Jestinah, Imai, Kentaro, and Haas, Naomi B.

Subjects
PEMBROLIZUMAB, RENAL cell carcinoma, RENAL cancer treatment, NEPHRECTOMY
Abstract

A Markov-based cost-effectiveness model was developed to project long-term effectiveness and costs among patients who undergo nephrectomy for renal cell carcinoma and receive either adjuvant pembrolizumab, adjuvant sunitinib, or routine surveillance alone (no adjuvant treatment). Over a lifetime horizon, pembrolizumab was estimated to prolong quality-adjusted life expectancy and be cost-effective relative to both comparator treatment strategies. Introduction: Pembrolizumab was recently approved as an adjuvant treatment of renal cell carcinoma (RCC), based on prolonged disease-free survival compared to placebo in the phase III KEYNOTE-564 trial. The objective of this study was to evaluate the cost-effectiveness of pembrolizumab as monotherapy in the adjuvant treatment of RCC post-nephrectomy, from a US health sector perspective. Patients and Methods: A Markov model with 4 health states (disease-free, locoregional recurrence, distant metastases, and death) was developed to compare the cost and effectiveness of pembrolizumab versus routine surveillance or sunitinib. Transition probabilities were estimated using patient-level KEYNOTE-564 data (cutoff: June 14, 2021), a retrospective study, and published literature. Costs of adjuvant and subsequent treatments, adverse events, disease management, and terminal care were estimated in 2022 US$. Utilities were based on EQ-5D-5L data collected in KEYNOTE-564. Outcomes included costs, life-years (LYs), and quality-adjusted LYs (QALYs). Robustness was assessed through one-way and probabilistic sensitivity analyses. Results: Total cost per patient was $549,353 for pembrolizumab, $505,094 for routine surveillance, and $602,065 for sunitinib. Over a lifetime, pembrolizumab provided gains of 0.96 QALYs (1.00 LYs) compared to routine surveillance, yielding an incremental cost-effectiveness ratio of $46,327/QALY. Pembrolizumab dominated sunitinib with 0.89 QALYs (0.91 LYs) gained while saving costs. At a $150,000/QALY threshold, pembrolizumab was cost-effective versus both routine surveillance and sunitinib in 84.2% of probabilistic simulations. Conclusion: Pembrolizumab is projected to be cost-effective as an adjuvant RCC treatment versus routine surveillance or sunitinib based on a typical willingness-to-pay threshold. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Source Reconstruction of the 1969 Western Sulawesi, Indonesia, Earthquake and Tsunami.

Author

Pranantyo, Ignatius R., Cipta, Athanasius, Shiddiqi, Hasbi A., Baba, Toshitaka, and Imai, Kentaro

Subjects
EARTHQUAKES, TSUNAMIS, GROUND motion, EARTHQUAKE intensity
Abstract

The island of Sulawesi, Indonesia, is located in a complex and tectonically active region, and has experienced tsunamis in the past. One of the major earthquake and tsunami events was the 23 February 1969 event that struck the Majene region in western Sulawesi Island. Interpretation of the historical accounts revealed that the Mw 7.0 earthquake generated strong intensity up to VIII on the Modified Mercalli Intensity scale. The earthquake was followed by an unusually high tsunami of 4 m that rapidly decayed within 25 km from the highest observation site. Hypocentre and earthquake mechanism analyses confirmed that it was an inland earthquake with a thrust mechanism. Ground motion modelling is able to reproduce the earthquake intensity but earthquake scenarios are unable to reconstruct the tsunami observations. A plausible solution to explain the tsunami report is from a combined scenario of an earthquake and a submarine mass failure of 0.5 km 3 . [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Author

Powles, Thomas, primary, Tomczak, Piotr, additional, Park, Se Hoon, additional, Venugopal, Balaji, additional, Ferguson, Thomas, additional, Symeonides, Stefan N, additional, Hajek, Jaroslav, additional, Gurney, Howard, additional, Chang, Yen-Hwa, additional, Lee, Jae Lyun, additional, Sarwar, Naveed, additional, Thiery-Vuillemin, Antoine, additional, Gross-Goupil, Marine, additional, Mahave, Mauricio, additional, Haas, Naomi B, additional, Sawrycki, Piotr, additional, Burgents, Joseph E, additional, Xu, Lei, additional, Imai, Kentaro, additional, Quinn, David I, additional, Choueiri, Toni K, additional, Choueiri, Toni, additional, Ferguson, Thomas R., additional, Lin, Tzu-Ping, additional, Symeonides, Stefan N., additional, Haas, Naomi B., additional, Gurney, Howard P., additional, Chevreau, Christine, additional, Burke, John M., additional, Doshi, Gurjyot, additional, Melichar, Bohuslav, additional, Topart, Delphine, additional, Oudard, Stephane, additional, Kopyltsov, Evgeniy, additional, Hammers, Hans-Joerg, additional, Quinn, David I., additional, Alva, Ajjai, additional, Menezes, Juliana de Janoski, additional, Silva, Adriano Goncalves e, additional, Winquist, Eric W., additional, Hamzaj, Alketa, additional, Procopio, Giuseppe, additional, Karaszewska, Boguslawa, additional, Nowakowska-Zajdel, Ewa M., additional, Alekseev, Boris Y., additional, Gafanov, Rustem A., additional, Izmailov, Adel, additional, Semenov, Andrey, additional, Afanasyev, Sergey G., additional, Lipatov, Oleg N., additional, Powles, Thomas B., additional, Srinivas, Sandy, additional, McDermott, David, additional, Kochuparambil, Samith T., additional, Davis, Ian D., additional, Peltola, Katriina, additional, Sabbatini, Roberto, additional, Chung, Jinsoo, additional, Shkolnik, Michail I., additional, Matveev, Vsevolod B., additional, Gajate Borau, Pablo, additional, McCune, Steven, additional, Hutson, Thomas E., additional, Dri, Alejandro, additional, Sales, Silvio Correia, additional, Yeung, Carrie, additional, Alcala Castro, Carmen Marcela, additional, Bostrom, Peter, additional, Laguerre, Brigitte, additional, Buttigliero, Consuelo, additional, de Giorgi, Ugo, additional, Fomin, Eugeniy A., additional, Zakharia, Yousef, additional, Hwang, Clara, additional, Singer, Eric A., additional, Yorio, Jeffrey T., additional, Waterhouse, David, additional, Kowalyszyn, Ruben Dario, additional, Alfie, Margarita Sonia, additional, Yanez Ruiz, Eduardo, additional, Buchler, Tomas, additional, Kankaanranta, Krista, additional, Ferretti, Gianluigi, additional, Kimura, Go, additional, Nishimura, Kazuo, additional, Masumori, Naoya, additional, Tamada, Satoshi, additional, Kato, Haruaki, additional, Kitamura, Hiroshi, additional, Danielewicz, Iwona, additional, Wojcik-Tomaszewska, Joanna, additional, Sala Gonzalez, Nuria, additional, Chiu, Kun-Yuan, additional, Atkins, Michael B., additional, Heath, Elisabeth, additional, Rojas-Uribe, Gustavo Adolfo, additional, Gonzalez Fernandez, Manuel Enrique, additional, Feyerabend, Susan, additional, Pignata, Sandro, additional, Numakura, Kazuyuki, additional, Cybulska Stopa, Bozena, additional, Zukov, Ruslan, additional, Climent Duran, Miguel Angel, additional, Maroto Rey, Pablo Jose, additional, Montesa Pino, Alvaro, additional, Chang, Chao-Hsiang, additional, Vengalil, Salil, additional, Waddell, Tom S., additional, Cobb, Patrick W., additional, Hauke, Ralph, additional, Anderson, Daniel M., additional, Sarantopoulos, John, additional, Gourdin, Theodore, additional, Zhang, Tian, additional, Jayram, Gautam, additional, Fein, Luis Enrique, additional, Harris, Carole, additional, Beato, Patricia Medeiros Milhomem, additional, Flores, Francisco, additional, Estay, Angela, additional, Rubiano, Juan Andres, additional, Bedke, Jens, additional, Hauser, Stefan, additional, Neisius, Andreas, additional, Busch, Jonas, additional, Anai, Satoshi, additional, Tsunemori, Hiroyuki, additional, Sawka, Dariusz, additional, Sikora-Kupis, Bozena, additional, Arranz, Jose Angel, additional, Delgado, Ignacio, additional, Chen, Chung-Hsin, additional, Gunderson, Elizabeth, additional, Tykodi, Scott, additional, Koletsky, Alan, additional, Chen, Kevin, additional, Agrawal, Manish, additional, Kaen, Diego Lucas, additional, Sade, Juan Pablo, additional, Tatangelo, Marcelo Daniel, additional, Parnis, Francis, additional, Barbosa, Fernando Maciel, additional, Faucher, Genevieve, additional, Iqbal, Nayyer, additional, Marceau, Daniele, additional, Paradis, Jean-Benoit, additional, Hanna, Nawar, additional, Acevedo, Alejandro, additional, Ibanez, Carolina, additional, Villanueva, Luis, additional, Galaz, Pedro Pablo, additional, Durango, Isabel Cristina, additional, Manneh, Ray, additional, Kral, Zdenek -, additional, Holeckova, Petra, additional, Hakkarainen, Heikki, additional, Ronkainen, Hanna, additional, Abadie-Lacourtoisie, Sophie, additional, Tartas, Sophie, additional, Goebell, Peter J., additional, Grimm, Marc-Oliver, additional, Hoefner, Thomas, additional, Wirth, Manfred, additional, Panic, Andrej, additional, Schultze-Seemann, Wolfgang, additional, Yokomizo, Akira, additional, Mizuno, Ryuichi, additional, Uemura, Hirotsugu, additional, Eto, Masatoshi, additional, Tsujihata, Masao, additional, Matsukawa, Yoshihisa, additional, Murakami, Yoji, additional, Kim, Miso, additional, Hamberg, Paul, additional, Marczewska-Skrodzka, Malgorzata, additional, Szczylik, Cezary, additional, Humphreys, Alison C., additional, Jiang, Peter, additional, Kumar, Birendra, additional, Lu, Gary, additional, Desai, Arpita, additional, Karam, Jose Antonio, additional, Keogh, George, additional, Fleming, Mark, additional, Zarba, Juan Jose, additional, Leiva, Viviana E., additional, Mendez, Guillermo Ariel, additional, Harris, Samuel J., additional, Brown, Stephen J., additional, Antonio Junior, Joao Neif, additional, Costamilan, Rita de Cassia, additional, Rocha, Roberto Odebrecht, additional, Muniz, David, additional, Brust, Leandro, additional, Lalani, Aly-Khan, additional, Graham, Jeffrey, additional, Levesque, Michael, additional, Orlandi, Francisco, additional, Kotasek, Rostislav, additional, Deville, Jean L., additional, Borchiellini, Delphine, additional, Merseburger, Axel, additional, Rink, Michael, additional, Roos, Frederik, additional, McDermott, Ray, additional, Oyama, Masafumi, additional, Yamamoto, Yoshiaki, additional, Tomita, Yoshihiko, additional, Miura, Yuji, additional, Ioritani, Naomasa, additional, Westgeest, Hans, additional, Kubiatowski, Tomasz, additional, Bal, Wieslaw, additional, Girones Sarrio, Regina, additional, Rowe, Julie, additional, Prow, Debra M., additional, Senecal, Francis, additional, Hashemi-Sadraei, Neda, additional, Cole, Scott W., additional, Kendall, Stephan D., additional, Richards, Donald A., additional, Schnadig, Ian D., additional, and Gupta, Mukul, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results